Search Within

Alexander Edward Drilon

  1. "Epidemiology and Biostatistics"
Formats
  1. Journal Article (42)
  2. Meeting Abstract (31)
  3. Correspondence (1)
  4. Research Letter (1)
Groups
  1. Department of Medicine (75)
  2. Epidemiology and Biostatistics (75)
  3. Solid Tumor Oncology Division (75)
  4. Thoracic Oncology (75)
  5. Biostatistics Service (62)
  6. GSK Faculty (55)

More Groups

People
  1. Bob Li (37)
  2. Charles Rudin (34)
  3. Maria Arcila (34)
  4. Mark Kris (28)
  5. Marc Ladanyi (27)
  6. Michael Berger (25)

More People

Years
  1. 2025 (2)
  2. 2024 (8)
  3. 2023 (6)
  4. 2022 (10)
  5. 2021 (8)
  6. 2020 (6)

More Years

Publications
  1. Journal of Clinical Oncology (23)
  2. Clinical Cancer Research (8)
  3. Journal of Thoracic Oncology (7)
  4. JCO Precision Oncology (5)
  5. Annals of Oncology (4)
  6. Cancer Discovery (4)

More Publications

Publishers
  1. American Society of Clinical Oncology (28)
  2. American Association for Cancer Research (13)
  3. Elsevier Inc. (13)
  4. Oxford University Press (6)
  5. Elsevier Ireland Ltd. (3)
  6. Wiley Blackwell (3)

More Publishers

Results (75)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • From genotype to phenotype: Are there imaging characteristics associated with lung adenocarcinomas harboring RET and ROS1 rearrangements?
    Journal Article

    Plodkowski, A. J.; Drilon, A.; Halpenny, D. F.; O'Driscoll, D.; Blair, D.; Litvak, A. M.; Zheng, J.; Moskowitz, C. S.; Ginsberg, M. S.
    Lung Cancer (2015)

    Fulltext@MSK | Save
  • Physician toxicity attribution in phase I trials: Evaluating the effect of dose on the frequency of 11,909 toxicities
    Meeting Abstract

    Eaton, A.; Iasonos, A.; Gounder, M. M.; Pamer, E.; Drilon, A. E.; Vulih, D.; Smith, G. L.; Ivy, P.; Spriggs, D. R.; Hyman, D. M.
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Dermatologic toxicities of 3,517 solid tumor patients on phase I clinical trials of the National Institutes of Health Cancer Therapy Evaluation Program (CTEP)
    Meeting Abstract

    Drilon, A. E.; Eaton, A.; Schindler, K.; Gounder, M. M.; Smith, G. L.; Vulih, D.; Harris, P. J.; Spriggs, D. R.; Ivy, P.; Iasonos, A.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring met mutations causing exon 14 skipping
    Journal Article

    Paik, P. K.; Drilon, A.; Fan, P. D.; Yu, H.; Rekhtman, N.; Ginsberg, M. S.; Borsu, L.; Schultz, N.; Berger, M. F.; Rudin, C. M.; more...
    Cancer Discovery (2015)

    Fulltext@MSK | Save
  • The role of EGFR and KRAS mutations in locally advanced lung adenocarcinoma treated with definitive radiation therapy
    Meeting Abstract

    Rimner, A.; Wang, H.; Tsang, M.; Drilon, A.; Paik, P. K.; Hsu, M.; Zhang, Z.; Rosenzweig, K. E.; Wu, A. J.; Zakowski, M. F.
    International Journal of Radiation Oncology, Biology, Physics (2012)

    Fulltext@MSK | Save